Regeneron Pharmaceuticals, Inc. (REGN) SEC Filings & Earnings Calls

Development risk for four new antibodies; Regeneron responsible for development costs above budget cap.

“Development costs in excess of a budget cap for all New Licensed Products will be the responsibility of Regeneron.” · word for word

Regulatory and commercial milestone achievement uncertain; $7B potential payments contingent on success.

“Up to $7.0B in milestone payments subject to development, regulatory, and commercial milestones.”

Fianlimab Phase 3 trial in melanoma missed primary endpoint

“The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab monotherapy.” · word for word

EYLEA franchise U.S. net sales declined 12% YoY due to shift to EYLEA HD

“Total EYLEA HD and EYLEA - U.S. $1,008 million vs $1,147 million, (12%)”

Bayer collaboration revenue declined 33% YoY

“Bayer $276 million vs $415 million, (33%)”

IPR&D charges impacting GAAP earnings

“GAAP EPS of $12.23, including $1.02 negative impact from IPR&D; non-GAAP EPS of $14.29, including $0.99 negative impact from IPR&D”

U.S. Government Pricing Agreements

“we have agreed, among other matters, to provide certain of our products that we wholly own in the United States to the Medicaid program at prices no greater than prices determined based on benchmarking against a defined group of other developed countries ("Most-Favored-Nation Pricing").” · word for word

Tariff Exposure on Imports

“tariffs of either 10% or 12.5%, effective July 24, 2026, apply to imports from 60 countries, including locations where we have operations, such as Canada, the European Union, India, Japan, and the United Kingdom.” · word for word

EYLEA Biosimilar Competition

“EYLEA net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.” · word for word

Sanofi Collaboration Litigation

“we have commenced the Antibody Collaboration Litigation against Sanofi and certain of its affiliated entities.” · word for word

Large IPR&D charge reduces reported earnings; uncertainty in future charges due to unpredictable deal timing.

“Acquired IPR&D charge of $127M; Regeneron does not forecast such charges due to uncertainty.”

U.S. Government Pricing Agreements

“we have agreed, among other matters, to provide certain of our products that we wholly own in the United States to the Medicaid program at or below prices benchmarked against a defined group of other developed countries ("Most-Favored-Nation Pricing")” · word for word

Tariff Exposure on Imports

“our products that are manufactured partly or entirely outside of the United States could be subject to tariff duties when they are imported to the United States for further manufacturing, packaging, and/or sale to customers” · word for word

Sanofi Collaboration Litigation

“we have commenced the Antibody Collaboration Litigation against Sanofi and certain of its affiliated entities” · word for word

EYLEA Competitive Pressure from Biosimilars

“EYLEA net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars” · word for word

IPR&D charges negatively impacting GAAP earnings; $0.82 per share impact

“GAAP EPS of $6.75, including $0.82 negative impact from IPR&D” · word for word

EYLEA HD PFS filling at Catalent Indiana still pending FDA approval; regulatory uncertainty

“FDA did not act by the April 2026 PDUFA date on the Company's regulatory application for a second contract manufacturer for the PFS; therefore, this application remains pending” · word for word

Third-party manufacturing filler dependency

“Ongoing challenges with third-party manufacturing fillers (which, while not directly related to the Company’s operations, had resulted in FDA observations and delayed filings and approvals).” · word for word

Clinical trial failure risk

“The results from a second Phase 3 trial for itepekimab, which did not meet its primary endpoint in 2025.” · word for word

Dual-class capital structure governance risk

“Regeneron currently has two classes of stock outstanding – common stock, par value $0.001 per share (“common stock”), which is entitled to one vote per share; and Class A stock, par value $0.001 per share (“Class A stock”), which is entitled to ten votes per share.” · word for word

Regulatory approval delays

“The FDA issued a CRL for the applicable regulatory application; the sole approvability issue related to unresolved inspection findings at a third-party manufacturer responsible for filling drug product.” · word for word

Recurring nature of IPR&D charges could impact earnings predictability.

“Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, certain development milestone payments, and premiums paid on equity securities related to collaboration and licensing agreements.” · word for word

Uncertainty around future charges; company does not forecast them.

“Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period.” · word for word

Manufacturing dependency on third-party supplier

“The FDA issued a CRL for the pre-filled syringe sBLA. The sole approvability issue cited in the CRL relates to unresolved inspection findings at Catalent.” · word for word

Biosimilar competition for EYLEA

“Biosimilar versions of EYLEA have been approved and/or launched both in and outside the United States, including Amgen's Pavblu (aflibercept-ayyh) (launched in the United States in the fourth quarter of 2024).” · word for word

Drug pricing regulation (IRA)

“The Medicare Drug Price Negotiation Program requires the government to set prices for select high-expenditure drugs covered under Medicare Parts B and D.” · word for word

Clinical trial failure (itepekimab COPD)

“A second Phase 3 trial, AERIFY-2, did not meet the same primary endpoint” · word for word

FDA clinical hold (nex-z ATTR-CM)

“Phase 3 ATTR-CM trial enrollment on FDA clinical hold” · word for word

Total EYLEA franchise U.S. net sales declined 27% in FY2025 due to competition or conversion to HD; potential revenue concentration risk.

“Total EYLEA HD and EYLEA U.S. net sales decreased 27% to $4.4 billion for FY 2025.” · word for word

Non-GAAP net income declined 8% in FY2025; GAAP net income up 2% but non-GAAP down; margin pressure from R&D or SG&A.

“Non-GAAP net income $4,888 million for FY 2025 vs $5,319 million for FY 2024, a decrease of 8%.”

Forward-looking statements and non-GAAP measures; no specific risk signals in excerpt

“Boilerplate risk factors and non-GAAP reconciliation note.”

Manufacturing risk: FDA CRL for EYLEA HD pre-filled syringe due to Catalent inspection issues.

“FDA issued a Complete Response Letter for the pre-filled syringe sBLA. The sole approvability issue cited relates to unresolved inspection findings at Catalent.”

Biosimilar competition for EYLEA

“EYLEA net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.” · word for word

FDA inspection issues at third-party manufacturer Catalent

“On October 27, 2025, the FDA issued a CRL for the pre-filled syringe sBLA. The sole approvability issue cited in the CRL relates to unresolved inspection findings at Catalent.” · word for word

Large contingent reimbursement obligation to Sanofi

“As of September 30, 2025, the total amount of our contingent reimbursement obligation to Sanofi (i.e., "development balance") in connection with such development expenses was approximately $905 million.” · word for word

Clinical hold on nex-z trials due to safety signal

“Intellia temporarily paused dosing and screening in Phase 3 ATTR-CM and ATTRv-PN trials due to a Grade 4 adverse event involving the liver” · word for word